Interpretation of plasma concentrations of human atrial natriuretic peptide (hANP) in congestive heart failure.
The present study reports about novel findings concerning the interrelationship between release of human atrial natriuretic factor (hANP) and the clinical situation of patients suffering from congestive heart failure. Estimations of plasma hANP were done by specific and sensitive extraction-based RIA. The normal range was 5 to 80 ng/l, mean +/- SEM = 30 +/- 15 ng/l, n = 106. Influence of response to therapy on hANP-release was studied in altogether 14 patients. 12 of these patients had elevated plasma hANP at admittance, surprisingly peptide levels were normal in 2 patients throughout the study. 9 out of the 14 patients responded well to therapy (shift from NYHA IV/III to NYHA II within about 10 days), hANP-levels decreased to normal values: 235 +/- 104 ng/l vs. 65 +/- 13 ng/l; p less than 0.001. The 5 residual patients responded to therapy only partially (shift from HYHA IV to NYHA III within an observation interval of about 2 weeks). Plasma hANP values decreased from 225 +/- 94 ng/l to 137 +/- 22 ng/l (p less than 0.02), but were still supranormal. Atrial fibrillation, which persisted in 8 out of the 14 patients after therapy did not influence hANP levels: hANP levels paralleled clinical signs of improvement, irrespective of atrial fibrillation. Right heart catheterization revealed very high mean right atrial pressures in those 2 patients mentioned above, who had normal pretherapeutic hANP.(ABSTRACT TRUNCATED AT 250 WORDS)
Hartter
E
E
II. Medizinischen Universitätsklinik Wien.
Weissel
M
M
Punzengruber
C
C
Burghuber
O C
OC
Woloszczuk
W
W
D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy; D001282:Atrial Flutter / Q000097:blood / Q000188:drug therapy; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001794:Blood Pressure / Q000502:physiology; D002302:Cardiac Output / Q000502:physiology; D009202:Cardiomyopathies / Q000097:blood / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006349:Heart Valve Diseases / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008137:Longitudinal Studies; D008297:Male
D002316:Cardiotonic Agents; D004232:Diuretics; D009320:Atrial Natriuretic Factor